In terms of important clinical, cytogenetic and molecular features, PHF6 mutation was significantly associated with IDH2 mutation (27% in PHF6mut AML vs. 2% in PHF6wtAML, p = 0.005), KRAS mutation (14% in PHF6mut AML vs. 0% in PHF6wtAML, p = 0.035) and +11 (14% in PHF6mutAML vs. 0% in PHF6wtAML, p = 0.035), and no differences were found in the odds of having other prognosis‐related gene mutations and important chromosomal aberrations. This evidence concerns the gene KRAS and acute myeloid leukemia.